Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Luis Castilla, Press Officer, Public Citizen’s Texas office
w. (512) 637-9467

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


March 27, 2014

No Basis for Serelaxin Approval, Public Citizen Tells FDA Advisory Committee

Drug Failed on All Counts in Pre-Approval Clinical Trial

WASHINGTON, D.C. – The U.S. Food and Drug Administration’s (FDA’s) Cardiovascular and Renal Drugs Advisory Committee should vote to reject the approval of serelaxin, a new medication intended to treat patients with acute heart failure, because the single study conducted to support approval demonstrated that the treatment was not effective in easing patients’ initial symptoms, Public Citizen said in a testimony today.

One million Americans are hospitalized every year for acute heart failure, one of the most common causes of hospital admissions in Americans 65 years of age and older. Serelaxin was developed to improve these patients’ symptoms during the first few days after admission to the hospital.

However, the treatment failed to show any meaningful benefit on the symptoms or progression of acute heart failure, despite the company’s best efforts to cast the data in a favorable light. The FDA’s clinical reviewer consequently recommended against approval of serelaxin, as did a key committee of the European Medicines Agency last January. However, in June 2013, the FDA prematurely labeled serelaxin a “Breakthrough Therapy” due to preliminary findings from the pivotal trial.

“The findings from the single trial conducted to support approval show that serelaxin not only is not a breakthrough medication, but it failed to meet even the modest goals – to improve patients’ symptoms – set out at the beginning of the study,” said Dr. Sammy Almashat, researcher with Public Citizen’s Health Research Group. “The advisory committee and the FDA should follow the advice of the FDA’s clinical reviewer and reject the drug, at least until data from an ongoing, larger trial are made available.”

See Public Citizen’s testimony.


Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.